XNAS · Healthcare · Biotechnology
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.56 | -0.20 | +64.29% | $13.4M | ✅ Beat | +0.97% | +11.95% | — |
| 2026-05-07 | Q1 2026 | -0.66 | -0.54 | +18.18% | $8.2M | ✅ Beat | -0.81% | -2.04% | -25.96% |
| 2026-03-19 |
| Q4 2025 |
| -0.71 |
| 1.30 |
| +283.10% |
| $42.5M |
| ✅ Beat |
| +0.00% |
| +4.94% |
| +6.29% |
| 2025-11-10 | Q3 2025 | -0.59 | -0.72 | -22.03% | $10.8M | ❌ Miss | — | — | — |
| 2025-08-06 | Q2 2025 | -1.73 | -1.33 | +23.12% | $9.6M | ✅ Beat | +0.36% | +27.38% | +22.57% |
| 2025-03-20 | Q4 2024 | -1.75 | -1.57 | +10.29% | $7.4M | ✅ Beat | +2.99% | +1.96% | -7.02% |
| 2024-11-07 | Q3 2024 | -2.02 | -1.51 | +25.25% | $6.8M | ✅ Beat | -4.11% | -2.57% | -4.60% |
| 2024-05-08 | Q1 2024 | -3.24 | -1.66 | +48.77% | $5.8M | ✅ Beat | +1.25% | +13.70% | +11.13% |
Showing last 8 quarters.